This information was published on 2025-11-27T15:33:41 for IP Right Filed Published.
| Field | Value |
| (210) | 2607742 |
| (220) |
27 Nov 2025
|
| (300) |
US, 24 Jun 2025, 99/250,874
|
| (511) (510) |
Class 5
pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of immunoglobulin A nephropathy; pharmaceutical preparations for the treatment of primary membranous nephropathy; pharmaceutical preparations for the treatment of lupus nephritis; pharmaceutical preparations for the treatment of renal anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis; pharmaceutical preparations for the treatment of immune thrombocytopenia; pharmaceutical preparations for the treatment of immune thrombocytopenia purpura; pharmaceutical preparations for the treatment of cold autoimmune hemolytic anemia; pharmaceutical preparations for the treatment of warm autoimmune hemolytic anemia; pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for the treatment of blood diseases and disorders; pharmaceutical preparations for the treatment of inflammation related diseases and disorders |
| (540) | BYPOVY |
| (550) | Word |
| (730) |
Vertex Pharmaceuticals Incorporated
|
| (750) |
PHILLIPS ORMONDE FITZPATRICK
|
Find out more about publications on the About page.